FDA Approves First Gene Therapy for Adults With Hemophilia B
MONDAY, Nov. 28, 2022 (HealthDay News) -- The U.S. Food and Drug Administration has approved Hemgenix (etranacogene dezaparvovec) for the treatment of hemophilia B in adults.
Hemgenix, an adeno-associated virus vector-based gene therapy, is administered via intravenous infusion as a one-time, single dose.
The approval was based on two studies of adult men (ages 18 to 75 years) with severe or moderately severe hemophilia B. Outcomes included increases in factor IX activity levels, a decreased need for routine factor IX replacement prophylaxis, and a 54 percent reduction in the annualized bleeding rate compared with baseline. Adverse reactions included liver enzyme elevations, headache, mild infusion-related reactions, and flu-like symptoms.
"Gene therapy for hemophilia has been on the horizon for more than two decades," Peter Marks, M.D., Ph.D., director of the FDA Center for Biologics Evaluation and Research, said in a statement. "Today's approval provides a new treatment option for patients with hemophilia B and represents important progress in the development of innovative therapies for those experiencing a high burden of disease associated with this form of hemophilia."
Approval of Hemgenix was granted to CSL Behring.
Related Posts
La detección temprana del glaucoma es esencial
VIERNES, 14 de julio de 2023 (HealthDay News) -- El tratamiento puede controlar...
Biden Administration Announces Details of Vaccination Requirements for Foreign Travelers
https://consumer.healthday.com/b-10-26-biden-admin... Credit:...
Ruptura y luego crisis: cuando el romance se acaba, la salud mental de los hombres puede desmoronarse
LUNES, 14 de febrero de 2022 (HealthDay News) -- Este día de San Valentín hay...
Depression and Asthma
When a person has asthma, a bout of depression or anxiety can trigger attacks...